Minimal Residual Disease Market Analysis

  • Report ID: 5723
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT

Minimal Residual Disease Market Segmentation:

Type Segment Analysis

The molecular segment in the minimal residual disease market is estimated to gain the largest revenue share of 60% in the year 2035. One of the primary growth drivers for the molecular segment is the continuous advancement in sensitivity and specificity of molecular MRD techniques. MRD assays must have broad applicability, precision, dependability, and high sensitivity (≥10−4). Additionally, the genetic target for molecular MRD analysis should be sensitive, and stable across time (i.e., present at both diagnosis and relapse) to reflect the dynamics of the malignant clone during therapy, and typical of the disease for all leukemic clones.

Collaborative efforts between research institutions, pharmaceutical companies, and healthcare providers continually validate the efficacy of molecular MRD techniques, fostering confidence in their clinical utility. A multicenter trial involving European institutions, published in Blood, validated the use of ASO-PCR in monitoring MRD in acute promyelocytic leukemia (APL).

Technology Segment Analysis

The flow cytometry segment will hold almost 56% of the revenue share on account of the increasing and pervasive use of flow cytometry to detect cancer cells as it is the most powerful tool available worldwide. Moreover, according to laboratory studies in clinical samples, assays utilizing polymerase chain reaction or flow cytometry can identify a single ALL cell out of 10,000–100,000 normal cells. For MRD monitoring, leukemia immunophenotypes, and antigen-receptor gene rearrangements characterize the great majority of patients; presently, around half of the cases exhibit appropriate gene fusions. Therefore, this technology of MRD will help to boost the market gains.

A useful technique for phenotyping microbial cells is flow cytometry, which makes it possible to quickly analyze and characterize a variety of microbial populations. It can recognize and categorize various bacterial species according to their phenotypic traits. Researchers can assess the number of various microbial species or cell types present in a sample using fluorescent dyes or antibodies that target specific microbial markers. This information can be used to gain insights into population dynamics and the composition of microbial communities.

Our in-depth analysis of the global market includes the following segments:

     Type

  • Molecular
  • Immunophenotypic

     End User

  • BFSI
  • Retail and eCommerce
  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

     Technology

  • PCR
  • Flow Cytometry
  • NGS

     Test Type

  • DNA-based Tests
  • RNA-based Tests
  • Immunological Tests

     Application

  • Leukemia
  • Lymphoma
  • Solid Tumors

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of minimal residual disease is assessed at USD 2.47 billion.

The global minimal residual disease market size was valued at over USD 2.21 billion in 2025 and is expected to expand at a CAGR of more than 13.3%, surpassing USD 7.7 billion revenue by 2035.

North America minimal residual disease market will secure over 42% share, driven by rising cancer cases and increasing adoption of minimal residual disease techniques, forecast period 2026–2035.

Key players in the market include Roche Diagnostics Corporation, Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories, Inc., Illumina, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Qiagen N.V., Adaptive Biotechnologies Corporation, Invivoscribe, Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos